 <h1>Cysteamine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of cysteamine include:</b> lethargy, vomiting, and anorexia. <b>Other side effects include:</b> skin rash.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cysteamine: oral capsule, oral capsule delayed release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cysteamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cysteamine:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>drowsiness</li>
<li>fever</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>skin rash</li>
<li>stomach pain</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>dizziness</li>
<li>headache</li>
<li>mental depression</li>
<li>sore throat</li>
<li>trembling</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Increased thirst</li>
<li>seizures</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>blurred or double vision</li>
<li>bone lesions</li>
<li>bulging soft spot on the head of an infant</li>
<li>change in the ability to see colors, especially blue or yellow</li>
<li>chills</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>cough</li>
<li>eye pain</li>
<li>hearing loss</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>loss of vision</li>
<li>pain behind the eyes</li>
<li>pain in the legs</li>
<li>pain with eye movement</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>reddish purple lines on the arms, face, legs, trunk, or groin</li>
<li>severe headache</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cysteamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Breath odor</li>
<li>constipation</li>
<li>hives or welts</li>
<li>redness of the skin</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
<li>weight loss</li>
</ul><p>
<!-- end oral capsule, oral capsule delayed release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cysteamine: oral capsule, oral delayed release capsule, oral granule enteric coated</i></p><h3>General</h3><p>The most common adverse events were vomiting, abdominal pain, nausea, anorexia, fever, diarrhea, lethargy, headache, and rash.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (35%), diarrhea (16%)</p>
<p><b>Common</b> (1% to 10%): Nausea, bad breath, abdominal pain, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal ulceration and bleeding, constipation, gastroenteritis, duodenitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (31%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Dehydration<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Lethargy (11%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, headache, encephalopathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Somnolence, seizures, convulsions, ataxia, confusion, tremor, hyperkinesia, jitteriness</p>
<p><b>Postmarketing reports</b>: Benign intracranial hypertension with papilledema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (22%)</p>
<p><b>Common</b> (1% to 10%): Fatigue, asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreasing hearing<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Cases of Ehlers-Danlos like syndrome and vascular disorders on elbows have been reported in children chronically treated with high doses of different cysteamine preparations.  In cases where histopathological examination of the skin was performed, the results suggested angioendotheliomatosis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, skin odor</p>
<p><b>Uncommon</b> (0.1% to 1%): Hair color changes, skin fragility (molluscoid pseudomotor on elbows)</p>
<p><b>Frequency not reported</b>: Urticaria</p>
<p><b>Postmarketing reports</b>: Skin lesions, skin striae, skin fragility<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function</p>
<p><b>Frequency not reported</b>: Elevated alkaline phosphatase<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Hypertension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal urine odor<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Leukopenia, anemia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis</p>
<p><b>Postmarketing reports</b>: Molluscoid pseudotumors<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Nervousness, abnormal thinking, depression, emotional lability, hallucinations, nightmares<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephrotic syndrome, interstitial nephritis, renal failure<sup>[Ref]</sup></p><p>Cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation.  In some cases, histology showed a membranous glomerulonephritis of the renal allograft and hypersensitivity interstitial nephritis.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Procysbi (cysteamine)." Raptor Pharmaceutical Corporation, Novato, CA. </p><p id="ref_2">2. "Product Information. Cystagon (cysteamine)." Mylan Pharmaceuticals, Morgantown, WV. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about cysteamine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cysteamine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cystagon, Procysbi</dd></dl>
<h3>Professional resources</h3>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nephropathic Cystinosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cysteamine: oral capsule, oral delayed release capsule, oral granule enteric coated</i></p><h3>General</h3><p>The most common adverse events were vomiting, abdominal pain, nausea, anorexia, fever, diarrhea, lethargy, headache, and rash.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (35%), diarrhea (16%)</p><p><b>Common</b> (1% to 10%): Nausea, bad breath, abdominal pain, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal ulceration and bleeding, constipation, gastroenteritis, duodenitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (31%)</p><p><b>Uncommon</b> (0.1% to 1%): Dehydration<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Lethargy (11%)</p><p><b>Common</b> (1% to 10%): Dizziness, headache, encephalopathy</p><p><b>Uncommon</b> (0.1% to 1%): Somnolence, seizures, convulsions, ataxia, confusion, tremor, hyperkinesia, jitteriness</p><p><b>Postmarketing reports</b>: Benign intracranial hypertension with papilledema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (22%)</p><p><b>Common</b> (1% to 10%): Fatigue, asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Decreasing hearing<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Cases of Ehlers-Danlos like syndrome and vascular disorders on elbows have been reported in children chronically treated with high doses of different cysteamine preparations.  In cases where histopathological examination of the skin was performed, the results suggested angioendotheliomatosis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, skin odor</p><p><b>Uncommon</b> (0.1% to 1%): Hair color changes, skin fragility (molluscoid pseudomotor on elbows)</p><p><b>Frequency not reported</b>: Urticaria</p><p><b>Postmarketing reports</b>: Skin lesions, skin striae, skin fragility<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function</p><p><b>Frequency not reported</b>: Elevated alkaline phosphatase<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Hypertension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal urine odor<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Leukopenia, anemia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis</p><p><b>Postmarketing reports</b>: Molluscoid pseudotumors<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Nervousness, abnormal thinking, depression, emotional lability, hallucinations, nightmares<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephrotic syndrome, interstitial nephritis, renal failure<sup>[Ref]</sup></p><p>Cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation.  In some cases, histology showed a membranous glomerulonephritis of the renal allograft and hypersensitivity interstitial nephritis.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Procysbi (cysteamine)." Raptor Pharmaceutical Corporation, Novato, CA. </p><p id="ref_2">2. "Product Information. Cystagon (cysteamine)." Mylan Pharmaceuticals, Morgantown, WV. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about cysteamine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cysteamine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nephropathic Cystinosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>